No CrossRef data available.
Article contents
Evaluation of preterm infants having bronchopulmonary dysplasia with echocardiography and serum biomarkers
Published online by Cambridge University Press: 31 May 2023
Abstract
Background and objectives:
Pulmonary hypertension is frequent in infants with bronchopulmonary dysplasia. Echocardiography is easy to perform, non-invasive, and recommended by guidelines even though solely it is not enough. Catheterisation is gold standard but invasive, expensive, and not cost effective. Therefore, we aimed to assess to find out the role of biomarkers besides echocardiography in the diagnosis of pulmonary hypertension in preterm with bronchopulmonary dysplasia.
Methods:
This study is done during the time period January 2016–2017. The diagnosis of pulmonary hypertension was assessed by echocardiography at 36 weeks later repeated at 3rd and 6th months. We also repeated biomarkers at 3rd and 6th months. The infants born ≤ 28 weeks in Erciyes University hospital who were diagnosed bronchopulmonary dysplasia were included. Infants with genetic syndromes, structural lung, and CHDs were excluded. Patients without bronchopulmonary dysplasia but having pulmonary hypertension due to other reasons and patients having echocardiograms without adequate images were excluded.
Results:
At initial, 21/59 patients had bronchopulmonary dysplasia-pulmonary hypertension (Group 1), 21/59 had no bronchopulmonary dysplasia-pulmonary hypertension (Group 2), and 17/59 had bronchopulmonary dysplasia without pulmonary hypertension (Group 3). Systolic pulmonary artery pressure and pulmonary vascular resistance were found high in Group 1 (36 mmHg; p <0.001, 1.25 Woods Unit; p < 0.0017, respectively). Tricuspid annular plane systolic excursion values of Group 1 were low. Median serum kallistatin levels of Group 1 were lower than the other groups (230.5 (114.5–300.5) µg/ml; p < 0.005). During the study period, pulmonary hypertension of 14/21 bronchopulmonary dysplasia-pulmonary hypertension resolved, six patients in Group 3 developed pulmonary hypertension. However, there was no difference in the biomarkers of these six patients.
Conclusion:
In the diagnosis and the follow-up of pulmonary hypertension in bronchopulmonary dysplasia patients, besides echocardiography kallistatin, gelsolin, NT-probrain natriuretic peptide, homocysteine, and cystatin-C levels can be used. Further studies were required with large sample sizes.
- Type
- Original Article
- Information
- Copyright
- © The Author(s), 2023. Published by Cambridge University Press
References
Al-Ghanem, G, Shah, P, Thomas, S, et al. Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. J Perinatol 2017; 37: 414–419.CrossRefGoogle ScholarPubMed
Stuart, B D, Sekar, P, Coulson, J D, Choi, S E J, McGrath-Morrow, S A, Collaco, J M. Healthcare utilization and respiratory morbidities in preterm infants with pulmonary hypertension. J Perinatol 2013; 33: 543–547.CrossRefGoogle ScholarPubMed
Krishnan, U, Feinstein, JA, Adatia, I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary Dysplasia. J Pediatr 2017; 188: 24–34.e1.CrossRefGoogle ScholarPubMed
Abman, SH, Hansmann, G, Archer, SL, et al. Pediatric pulmonary hypertension. Circulation 2015; 132: 2037–2099.10.1161/CIR.0000000000000329CrossRefGoogle ScholarPubMed
Higgins, RD, Jobe, AH, Koso-Thomas, M, et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr 2018; 197: 300–308.CrossRefGoogle ScholarPubMed
Jensen, EA, Dysart, K, Gantz, MG, et al. The diagnosis of bronchopulmonary Dysplasia in very preterm infants an evidence-based approach. Am J Respir Crit Care Med 2019; 200: 751–759.CrossRefGoogle ScholarPubMed
Bossone, E, D’Andrea, A, D’Alto, M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr 2013 Jan; 26: 1–14.CrossRefGoogle ScholarPubMed
Abbas, AE, Fortuin, FD, Schiller, NB, Appleton, CP, Moreno, CA, Lester, SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003; 41: 1021–1027.CrossRefGoogle ScholarPubMed
Ryan, T, Petrovic, O, Dillon, JC, Feigenbaum, H, Conley, MJ, Armstrong, WF. An echocardiographic index for separation of right ventricular volume and pressure overload. J Am Coll Cardiol 1985; 5: 918–927.CrossRefGoogle ScholarPubMed
Feissel, M, Michard, F, Faller, J-P, Teboul, J-L. The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. Intensive Care Med 2004; 30: 1834–1837.CrossRefGoogle ScholarPubMed
An, HS, Bae, EJ, Kim, GB, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J. 2010; 40: 131–136.CrossRefGoogle ScholarPubMed
Wolf, WC, Sluce, D, Chao, L, Chao, J, Harley, RA. Cellular localization of kallistatin and tissue kallikrein in human pancreas and salivary glands. Histochem Cell Biol 1998; 110: 477–484.CrossRefGoogle ScholarPubMed
Gislefoss, RE, Grimsrud, TK, Mørkrid, L. Stability of selected serum proteins after long term storage in the Janus serum bank. Clin Chem Lab Med 2009; 47: 596–603.CrossRefGoogle ScholarPubMed
Weismann, C G, Asnes, J D, Bazzy-Asaad, A, Tolomeo, C, Ehrenkranz, R A, Bizzarro, M J. pulmonary hypertension in preterm infants: results of a prospective screening program. J Perinatol 2017; 37: 572–577.CrossRefGoogle ScholarPubMed
Vayalthrikkovil, S, Vorhies, E, Stritzke, A, et al. Prospective study of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia pediatric pulmonology. Pediatr Pulmonol 2019; 54: 171–178.CrossRefGoogle Scholar
Abman, SH, Hansmann, G, Archer, SL, et al. Pediatric pulmonary hypertension guidelines from the American heart association and American thoracic society. Circulation 2015; 132: 21–99.10.1161/CIR.0000000000000329CrossRefGoogle ScholarPubMed
McCrary, AW, Malowitz, JR, Hornik, CP, et al. Differences in eccentricity index and systolic-diastolic ratio in extremely low birth weight infants with bronchopulmonary dysplasia at risk of pulmonary hypertension am J perinatol. Am J Perinatol 2016; 33: 57–62. DOI 10.1055/s-0035-1556757.CrossRefGoogle Scholar
Mourani, PM, Sontag, MK, Younoszai, A, Ivy, DD, Abman, SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008; 121: 317–325.CrossRefGoogle ScholarPubMed
Slaughter, J L, Pakrashi, T, Jones, D E, South, A P, Shah, T A. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011; 31: 635–640.CrossRefGoogle ScholarPubMed
Vijlbrief, DC, Benders, MJNL, Kemperman, H, van Bel, F, de Vries, WB. Use of cardiac biomarkers in neonatology. Pediatr Res 2012; 72: 337–343.CrossRefGoogle ScholarPubMed
Vijlbrief, DC, Benders, MJNL, Kemperman, H, van Bel, F, de Vries, WB. B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 2012; 160: 111–115.CrossRefGoogle ScholarPubMed
Kim, JH, Huh, J, Lee, SI, et al. Analysis of clinical course and the prognosis of pulmonary hypertension in infants with bronchopulmonary dysplasia: a single center study. Pediatr Allergy Resp Dis 2008; 18: 243–252.Google Scholar
Pamukçu, Ö., Ay, D, Üzüm, K, et al. Role of kallistatin in pediatric patients with pulmonary arterial hypertension. Turk J Pediatr 2020; 62: 405–410.CrossRefGoogle ScholarPubMed
Sun, L, Sun, S, Li, Y, et al. Potential biomarkers predicting risk of pulmonary hypertension in congenital heart disease: the role of homocysteine and hydrogen sulfide. Chin Med J (Engl) 2014; 127: 893–899.CrossRefGoogle ScholarPubMed
Fenster, BE, Lasalvia, L, Schroeder, JD, et al. Cystatin C: a potential biomarker for pulmonary arterial hypertension. Respirology 2014; 19: 583–589.CrossRefGoogle ScholarPubMed